galantamine has been researched along with Cognitive Dysfunction in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (62.50) | 24.3611 |
| 2020's | 6 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Chiba, T; Fukuma, K; Ihara, M; Ikeda, S; Kitajima, E; Noda, K; Saito, S; Tanaka, T; Washida, K; Yoshimoto, T | 1 |
| Cui, Y; Ren, G; Shi, X; Xu, Z | 1 |
| Allam, M; El-Ganainy, SO; Elbahnasi, AI; Ghazy, AA; Gowayed, MA; Mansour, AM; Soliman, OA | 1 |
| Ahuja, M; Gabor, C; Karimi, A; Lee, J; Lewis, K; Patterson, C; Reppas-Rindlisbacher, C; Siddhpuria, S; Sood, E; Wong, E | 1 |
| Barkhof, F; Groeneveld, GJ; Klaassen, ES; Leeuwis, AE; Leijenaar, JF; Prins, ND; Scheltens, P; van der Flier, WM; van Gerven, JMA; Weinstein, HC | 1 |
| Hong, H; Hou, W; Koola, MM; Looney, SW; Pillai, A | 1 |
| Buchanan, RW; Carpenter, WT; Gold, JM; Kelly, DL; Koola, MM; McMahon, RP; Strauss, GP; Weiner, E | 1 |
| Aaronson, ST; Davis, W; Koola, MM; Kozak, R; Meissen, JK; Nikiforuk, A; Sawant-Basak, A; Sklar, J | 1 |
| Iyo, M; Oda, Y; Okubo, T; Sato, K; Shirayama, Y; Takahashi, M; Yoshino, K | 1 |
| Koola, MM | 1 |
| Bauer, C; Frölich, L; Heuser, I; Joachim, LK; Kornhuber, J; Maier, W; Peters, O; Rüther, E; Wiltfang, J | 1 |
| Bondi, CO; Cheng, JP; Kline, AE; Kutash, LA; Marshall, IP; Nicholas, MA; Njoku, I; O'Neil, DA; Radabaugh, HL | 1 |
| Ashoor, HM; Berliner, S; Chen, MH; Hemmelgarn, B; Ho, JM; Ng, CH; Soobiah, C; Straus, SE; Tricco, AC | 1 |
| Shoji, M | 1 |
| Bondi, CO; Cheng, JP; de la Tremblaye, PB; Kline, AE; Lajud, N; Radabaugh, HL | 1 |
| Fesche, A; Frölich, L; Gertz, HJ; Heuser, I; Hüll, M; Jahn, H; Jessen, F; Kornhuber, J; Lorenz, D; Luckhaus, C; Maier, W; Möller, HJ; Pantel, J; Perneczky, R; Peters, O; Rüther, E; Schmidtke, K; Schröder, J; Teipel, S; Wellek, S | 1 |
6 review(s) available for galantamine and Cognitive Dysfunction
| Article | Year |
|---|---|
Comparative Efficacy and Acceptability of Cholinesterase Inhibitors and Memantine Based on Dosage in Patients with Vascular Cognitive Impairment: A Network Meta-analysis.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Galantamine; Humans; Indans; Memantine; Network Meta-Analysis; Nootropic Agents; Randomized Controlled Trials as Topic; Rivastigmine | 2022 |
Cholinesterase inhibitors and falls, syncope and injuries in patients with cognitive impairment: a systematic review and meta-analysis.
Topics: Accidental Falls; Accidental Injuries; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Fractures, Bone; Galantamine; Humans; Rivastigmine; Syncope | 2023 |
Meta-analysis of randomized controlled trials of galantamine in schizophrenia: significant cognitive enhancement.
Topics: Cognition; Cognitive Dysfunction; Drug Therapy, Combination; Galantamine; Humans; Nootropic Agents; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology | 2020 |
Galantamine-Memantine Combination for Cognitive Impairments Due to Electroconvulsive Therapy, Traumatic Brain Injury, and Neurologic and Psychiatric Disorders: Kynurenic Acid and Mismatch Negativity Target Engagement.
Topics: Animals; Cognitive Dysfunction; Drug Therapy, Combination; Electroconvulsive Therapy; Galantamine; Humans; Kynurenic Acid; Memantine; Mental Disorders; Nervous System Diseases; Nootropic Agents | 2018 |
Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis.
Topics: Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2013 |
[Programs for continuing medical education: a session; 3. Dementia: diagnosis and therapy].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Cholinesterase Inhibitors; Cognitive Dysfunction; Dementia; Disease Progression; Donepezil; Education, Medical, Continuing; Galantamine; Humans; Indans; Lewy Body Disease; Nootropic Agents; Peptide Fragments; Phenylcarbamates; Piperidines; Positron-Emission Tomography; Reference Standards; Rivastigmine; tau Proteins; Tomography, Emission-Computed, Single-Photon | 2014 |
4 trial(s) available for galantamine and Cognitive Dysfunction
| Article | Year |
|---|---|
Methylphenidate and galantamine in patients with vascular cognitive impairment-the proof-of-principle study STREAM-VCI.
Topics: Aged; Central Nervous System Stimulants; Cognitive Dysfunction; Cross-Over Studies; Dementia, Vascular; Double-Blind Method; Executive Function; Female; Galantamine; Humans; Male; Memory; Methylphenidate; Middle Aged; Nootropic Agents; Proof of Concept Study | 2020 |
A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia.
Topics: Administration, Intranasal; Adult; Cognitive Dysfunction; Double-Blind Method; Female; Galantamine; Humans; Male; Middle Aged; Nootropic Agents; Oxytocics; Oxytocin; Pessimism; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2017 |
Kynurenine pathway in schizophrenia: Galantamine-memantine combination for cognitive impairments.
Topics: Adolescent; Adult; Cognitive Dysfunction; Drug Therapy, Combination; Female; Galantamine; Humans; Kynurenine; Male; Memantine; Middle Aged; Neuropsychological Tests; Nootropic Agents; Retrospective Studies; Schizophrenia; Signal Transduction; Young Adult | 2018 |
A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI.
Topics: Aged; Alzheimer Disease; Amnesia; Cholinesterase Inhibitors; Cognition; Cognitive Dysfunction; Cohort Studies; Dementia; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Early Termination of Clinical Trials; Female; Galantamine; Germany; Humans; Male; Memantine; Middle Aged; Nootropic Agents; Psychiatric Status Rating Scales; Receptors, N-Methyl-D-Aspartate | 2012 |
6 other study(ies) available for galantamine and Cognitive Dysfunction
| Article | Year |
|---|---|
A Nationwide Multi-Center Questionnaire Survey on the Real-World State and Clinical Management of Poststroke Dementia in Japan.
Topics: Aged; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Donepezil; Female; Galantamine; Humans; Japan; Male; Memantine; Mental Status and Dementia Tests; Stroke; Surveys and Questionnaires | 2021 |
Intranasal Oxytocin Attenuates Cognitive Impairment, β-Amyloid Burden and Tau Deposition in Female Rats with Alzheimer's Disease: Interplay of ERK1/2/GSK3β/Caspase-3.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Caspase 3; Cognitive Dysfunction; Disease Models, Animal; Female; Galantamine; Glycogen Synthase Kinase 3 beta; MAP Kinase Signaling System; Oxytocin; Rats; tau Proteins | 2022 |
rCBF and cognitive impairment changes assessed by SPECT and ADAS-cog in late-onset Alzheimer's disease after 18 months of treatment with the cholinesterase inhibitors donepezil or galantamine.
Topics: Aged; Alzheimer Disease; Brain; Brain Mapping; Cerebrovascular Circulation; Cholinesterase Inhibitors; Cognitive Dysfunction; Cross-Sectional Studies; Donepezil; Female; Follow-Up Studies; Galantamine; Humans; Imaging, Three-Dimensional; Male; Regional Blood Flow; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2019 |
Correlation of CSF- and MRI-Biomarkers and Progression of Cognitive Decline in an Open Label MCI Trial.
Topics: Activities of Daily Living; Amygdala; Amyloid beta-Peptides; Biomarkers; Cognitive Dysfunction; Disease Progression; Double-Blind Method; Female; Galantamine; Hippocampus; Humans; Magnetic Resonance Imaging; Male; Memantine; Neuroimaging; Neuropsychological Tests; Peptide Fragments; Randomized Controlled Trials as Topic; tau Proteins; Withholding Treatment | 2018 |
Chronic treatment with galantamine rescues reversal learning in an attentional set-shifting test after experimental brain trauma.
Topics: Animals; Attention; Brain Injuries, Traumatic; Cerebral Cortex; Cognitive Dysfunction; Dose-Response Relationship, Drug; Executive Function; Galantamine; Injections, Intraperitoneal; Male; Nootropic Agents; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Reversal Learning | 2019 |
Galantamine and Environmental Enrichment Enhance Cognitive Recovery after Experimental Traumatic Brain Injury But Do Not Confer Additional Benefits When Combined.
Topics: Animals; Behavior, Animal; Brain Injuries, Traumatic; Cholinesterase Inhibitors; Cognitive Dysfunction; Combined Modality Therapy; Disease Models, Animal; Environment; Galantamine; Male; Maze Learning; Neurological Rehabilitation; Psychomotor Performance; Rats; Rats, Sprague-Dawley | 2017 |